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Brief Definitive Report

Anti-apoE immunotherapy inhibits amyloid
accumulation in a transgenic mouse model
of AB amyloidosis
Jungsu Kim,1,2,3 Adam E.M. Eltorai,1,2,3 Hong Jiang,1,2,3 Fan Liao,1,2,3
Philip B. Verghese,1,2,3 Jaekwang Kim,1,2,3 Floy R. Stewart,1,2,3
Jacob M. Basak,1,2,3 and David M. Holtzman1,2,3
of Neurology, 2Hope Center for Neurological Disorders, and the 3Knight Alzheimer’s Disease Research Center,
Washington University School of Medicine, Saint Louis, MO 63110

The apolipoprotein E (APOE) b4 allele is the strongest genetic risk factor for Alzheimer’s
disease (AD). The influence of apoE on amyloid B (AB) accumulation may be the major
mechanism by which apoE affects AD. ApoE interacts with AB and facilitates AB fibrillogenesis in vitro. In addition, apoE is one of the protein components in plaques. We hypothesized
that certain anti-apoE antibodies, similar to certain anti-AB antibodies, may have antiamyloidogenic effects by binding to apoE in the plaques and activating microglia-mediated
amyloid clearance. To test this hypothesis, we developed several monoclonal anti-apoE
antibodies. Among them, we administered HJ6.3 antibody intraperitoneally to 4-mo-old male
APPswe/PS1$E9 mice weekly for 14 wk. HJ6.3 dramatically decreased amyloid deposition by
60–80% and significantly reduced insoluble AB40 and AB42 levels. Short-term treatment
with HJ6.3 resulted in strong changes in microglial responses around AB plaques. Collectively,
these results suggest that anti-apoE immunization may represent a novel AD therapeutic
strategy and that other proteins involved in AB binding and aggregation might also be a
target for immunotherapy. Our data also have important broader implications for other
amyloidosis. Immunotherapy to proteins tightly associated with misfolded proteins might
open up a new treatment option for many protein misfolding diseases.

CORRESPONDENCE
David M. Holtzman:
holtzman@neuro.wustl.edu
Abbreviations used: AB, amyloid
B; AD, Alzheimer’s disease;
APOE, apolipoprotein E;
APP, AB precursor protein; PS,
presenilin; RIPA, radioimmunoprecipitation assay.

Accumulation of amyloid B (AB) peptide in
the brain is hypothesized to initiate pathogenic
cascades that lead to Alzheimer’s disease (AD;
Golde et al., 2011; Holtzman et al., 2011).
Therapeutic strategies to inhibit AB accumulation, such as AB immunotherapy, are currently
being tested as disease-modifying therapies
(Golde et al., 2011; Holtzman et al., 2011). Sequential proteolytic cleavages of AB precursor
protein (APP) by B- and G-secretase produce
the AB peptide. Although rare, early-onset AD
mutations in the APP, presenilin 1 (PS1), and
PS2 genes have supported the critical role of
AB in AD pathogenesis, the d4 allele of apolipoprotein E (APOE) gene is the strongest genetic
risk factor for the common late-onset form of
AD, and the d2 allele is protective (Kim et al.,
2009a). Among several mechanisms proposed
to explain the effects of apoE on AD pathogenesis, prevailing evidence suggests that apoE’s
effect on AB accumulation may be the major
mechanism (Kim et al., 2009a). ApoE appears
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to affect AB accumulation by modulating both
AB aggregation and clearance (Ma et al., 1994;
Wisniewski et al., 1994; Castano et al., 1995;
Sadowski et al., 2006; Deane et al., 2008; Jiang
et al., 2008; Castellano et al., 2011). Along
with other amyloid-associated proteins, apoE
is found in amyloid plaques (Namba et al., 1991;
Wisniewski and Frangione, 1992). In this study,
we hypothesized that after peripheral administration of monoclonal anti-apoE antibodies,
the small fraction of anti-apoE antibodies that
enter the brain would bind to apoE in plaques
and decrease AB accumulation by activating
microglia-mediated clearance of AB aggregates,
similar to what has been described for certain
anti-AB antibodies (Bard et al., 2000; Brody
and Holtzman, 2008).
© 2012 Kim et al. This article is distributed under the terms of an Attribution–
Noncommercial–Share Alike–No Mirror Sites license for the first six months after
the publication date (see http://www.rupress.org/terms). After six months it is
available under a Creative Commons License (Attribution–Noncommercial–Share
Alike 3.0 Unported license, as described at http://creativecommons.org/licenses/
by-nc-sa/3.0/).
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RESULTS AND DISCUSSION
Generation and characterization of anti-apoE antibodies
To characterize anti-apoE antibodies, we evaluated their performance in Western blotting, ELISA, immunohistochemistry,
and immunoprecipitation. For Western blotting application,
cortical tissues from wild-type C57BL6/CBA background
mice were lysed with radioimmunoprecipitation assay (RIPA)
buffer and used for detection of apoE protein. Cortical tissue

lysates from apoe KO mice were used as negative controls.
Among four HJ antibodies tested, HJ6.3 antibody (IgG2b isotype) gave the strongest signal in Western blotting (Fig. 1 A).
When the membranes were overexposed, other antibodies also
recognized apoE (Fig. 1 B). For sandwich ELISA application,
anti-apoE antibody (WUE4) was used as a capture antibody,
and then a different concentration of lipid-free apoE protein
(0, 0.25, 0.74, 2.22, 6.67, 20, 60, and 180 ng/ml) was added to
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Figure 1. Characterization of anti-apoE antibodies. Four different anti-apoE antibodies were tested for their ability to recognize apoE in Western
blotting (A and B), ELISA (C), immunohistochemistry (D–H), and immunoprecipitation (I). (A and B) Cerebral cortical tissues from wild-type and apoe KO
mice were lysed with RIPA buffer and equal amounts of total proteins were loaded to each well. In B, the membranes shown in A were overexposed to
show a weak apoE band in the membranes probed with HJ6.1, HJ6.2, and HJ6.4 antibody. (C) ELISA plates were coated with anti-apoE antibody (WUE4),
and each biotinylated HJ antibody was used as a detection antibody. Optical density at 650 nm was measured with a series of different apoe concentrations. (D–G) Biotinylated HJ antibody was used as a primary antibody in the immunohistochemical staining with APPswe/PS1$E9 mice brain tissues.
Bar, 50 μm. (H) Biotinylated HJ6.3 antibody was used as a primary antibody in the immunohistochemical staining with brain tissues from apoE-deficient
APPswe/PS1$E9 mice. Bar, 50 μm. (I and J) Cerebral cortical tissues from wild-type mice were lysed with RIPA buffer, and the RIPA lysates were used for
immunoprecipitation with each HJ antibody. ApoE proteins left in the supernatant of postimmunoprecipitation (Post-IP) solution (I) and eluted from
protein G–Sepharose beads (J) were detected with a polyclonal anti-apoE antibody (EMD Millipore).
2150
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Figure 2. Reduction of AB plaque depositions
by anti-apoE immunotherapy. 4-mo-old male
APPswe/PS1$E9 mice were intraperitoneally injected
with PBS vehicle or anti-apoE antibody (HJ6.3) weekly
for 14 wk. (A and B) Brain sections from 7-mo-old
mice were immunostained for AB plaques with antiAB antibody (82E1-biotin). Bar, 250 μm. The extent of
AB plaque load was quantified in cortex (C) and hippocampus (D). The number of plaques per unit area
was quantified in cortex (E) and hippocampus (F).
n = 7 for PBS group; n = 18 for HJ6.3 group. To
determine the statistical significance (***, P < 0.001),
a two-tailed Student’s t test was used. Variance in all
graphs represents SEM.

JEM Vol. 209, No. 12

(Fig. 1 H). For immunoprecipitation application, each HJ antibody was first covalently conjugated to Sepharose beads and
then incubated with 1% Triton X-100 cortical tissue lysates.
The supernatants from immunoprecipitation (Fig. 1 I) and the
eluents from the Sepharose beads (Fig. 1 J) were used in Western blotting to assess efficiency of immunoprecipitation. Levels
of apoE were measured using a polyclonal anti-apoE antibody
(EMD Millipore) by Western blotting. HJ6.3 antibody was the
only antibody that was able to bind to apoE in cortical tissue
lysates, resulting in successful immunoprecipitation.
Anti-apoE immunotherapy inhibits
amyloid accumulation in the brain
Given its ability to detect apoE in amyloid plaques (Fig. 1 F),
we selected HJ6.3 antibody for anti-apoE immunization experiments. To determine whether anti-apoE antibody would
have an antiamyloidogenic effect, we injected PBS or antiapoE antibody (HJ6.3) weekly at 10 mg of antibody/kg of
body weight per dose. 4-mo-old male APPswe/PS1$E9 mice
were intraperitoneally injected for 14 wk. Brain tissues were
processed for histochemical and biochemical analyses. Quantitative analyses of anti-AB immunostaining (Fig. 2, A and B)
2151
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each well in the ELISA plates. Each biotinylated HJ antibody
was used as a detection antibody in the sandwich ELISA format (Fig. 1 C). Although all HJ6 antibodies recognized apoE
in the ELISA, HJ6.1 antibody (IgG1 isotype) generated the
strongest signals. Although HJ6 antibodies were initially
screened based on their recognition of purified, astrocytesecreted, lipidated apoE lipoprotein particles, all of them also
recognized lipid-free apoE (Fig. 1, A–C).
To determine whether HJ antibodies can detect apoE in
amyloid plaques in the brain, we stained brain tissue sections
from amyloid plaque–bearing 7-mo-old APPswe/PS1$E9
mice (Jankowsky et al., 2004; Fig. 1, D–G). HJ6.3 antibody
was the only antibody that recognized apoE associated with
amyloid plaques and in astrocytes, which are the major producers of apoE in the brain (Kim et al., 2009a; Fig. 1 F). To
evaluate the specificity of HJ6.3 antibody to apoE, we used
cortical tissues from APPswe/PS1$E9 mice that lacked the
apoe gene (APP/PS1/apoe/ mice) as negative controls. When
HJ6.3 antibody was used as a primary antibody in the immunohistochemical staining, it did not give any detectable signal
with the tissues from APP/PS1/apoe/ mice, thereby validating the specificity of HJ6.3 antibody to apoE in tissue sections
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Figure 3. Attenuation of fibrillar amyloid
accumulations by anti-apoE immunotherapy.
(A and B) Brain sections from male mice injected
with PBS or HJ6.3 antibody were stained with X-34
dye that recognizes only fibrillar plaques with a
B-sheet conformation. Bar, 150 μm. The extent of
fibrillar plaque load was quantified from cortex
(C) and hippocampus (D). The number of fibrillar
plaques per unit area was quantified from cortex
(E) and hippocampus (F). n = 7 for PBS group;
n = 18 for HJ6.3 group. Variance in all graphs
represents SEM.
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levels were observed in the cortex (Fig. 4, A and B) and hippocampus (Fig. 4, C and D) of mice treated with HJ6.3
antibody. Collectively, our results clearly demonstrate that
anti-apoE antibody HJ6.3 treatment dramatically inhibits AB
aggregation and amyloid accumulation in the brain.
Anti-apoE antibody treatment does not affect
levels of cholesterol and apoE
ApoE lipoprotein plays a key role in the receptor-mediated
endocytosis of lipoprotein particles in the plasma, thereby
regulating plasma cholesterol levels (Kim et al., 2009a). It
is conceivable that long-term treatment of anti-apoE antibody may alter plasma cholesterol metabolism by interfering with a normal function of apoE in the periphery. To
assess this potential concern, we measured total cholesterol
levels in the plasma from the APP/PS1 mice treated for 14 wk.
No significant difference in total cholesterol levels was observed between the PBS-treated and HJ6.3 antibody-treated
groups (PBS group, 151.0 ± 13.82 mg/dl; HJ6.3 group,
140.0 ± 12.45 mg/dl; P = 0.598; 95% confidence interval,
Anti-apoE antibody inhibits amyloid accumulation. | Kim et al.
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demonstrated that AB plaque load in the cortex (Fig. 2 C) and
hippocampus (Fig. 2 D) was markedly decreased by HJ6.3
antibody treatment, compared with the PBS-treated control
group. There was a strong 70–80% reduction in AB plaque
load in the cortex (Fig. 2 C) and hippocampus (Fig. 2 D).
HJ6.3 treatment also significantly decreased the number of
plaques per area in the cortex (Fig. 2 E) and hippocampus
(Fig. 2 F). To further characterize the structural nature of the
deposited AB plaques, brain sections were stained with X-34
dye that selectively recognizes only fibrillar AB deposits (Fig. 3,
A and B). Consistent with the anti-AB antibody staining results
(Fig. 2), the HJ6.3-treated group had significantly less X-34–
positive fibrillar plaque load (Fig. 3, C and D) and a decrease in
the number of fibrillar plaques per area (Fig. 3, E and F) in the
cortex (Fig. 3, C and E) and hippocampus (Fig. 3, D and F).
To determine the effect of HJ6.3 antibody on insoluble AB
accumulation, we performed AB end-specific ELISA. Cortical
and hippocampal tissues were sequentially homogenized with
PBS and 5 M guanidine HCl buffer. Significant reductions in
insoluble AB40 (Fig. 4, A and C) and AB42 (Fig. 4, B and D)
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Figure 4. Decrease of insoluble AB levels by antiapoE immunotherapy. Cortical and hippocampal tissues from male mice injected with PBS or HJ6.3 antibody
were first homogenized with PBS. Aggregated forms of
AB in the PBS-insoluble pellet were solubilized with 5M
guanidine HCl buffer. Insoluble AB40 (A) and AB42
(B) levels in cortex were measured using an AB-end
specific ELISA. Similarly, insoluble AB40 (C) and AB42
(D) levels in hippocampus were measured using AB
end-specific ELISA. n = 7 for PBS group; n = 18 for
HJ6.3 group. Variance in all graphs represents SEM.

Anti-apoE antibody treatment recruits microglia around
plaques and decreases levels of proinflammatory cytokines
Several mechanisms have been proposed to explain the beneficial effects of anti-AB immunotherapy (Brody and Holtzman,
2008; Golde et al., 2009). Among them, recruitment and
activation of microglia triggered by antibody in the brain
appears to be one of main underlying mechanisms (Koenigsknecht-Talboo et al., 2008; Wang et al., 2011). The level of
HJ6.3 antibody detected in the brain 24 h after a single injection was 0.096 ± 0.019% of the level present in the plasma.
To determine whether HJ6.3 antibody can increase the
amount of microglia around plaques, we quantified CD45+
microglia after short-term treatment of HJ6.3 antibody (intraperitoneal injection 4 times every 3 d) in mice that already
had existing plaques at 9 mo of age. Brain tissues were collected 1 d after the fourth injection. To quantitatively assess
the extent of microglial activation, we used an anti-CD45
antibody that recognizes activated microglia around plaques
JEM Vol. 209, No. 12

(Fig. 5, A and B). Previous studies demonstrated that fibrillar
amyloid plaques are strongly associated with the activation of
microglia (Lucin and Wyss-Coray, 2009). Because we used
9-mo-old APPswe/PS1$E9 mice with preexisting fibrillar
plaques (Jankowsky et al., 2004), we calculated HJ6.3-induced
microglial activation after normalizing with fibrillar plaque
load. Fibrillar plaque load was measured from subsequent
adjacent sections (50 μm apart) stained with the fibrillar amyloid–detecting dye X-34. Quantitative analyses indicted that
anti-apoE antibody HJ6.3 significantly increased CD-45 staining associated with amyloid plaques (Fig. 5 C), suggesting
HJ6.3-mediated recruitment of microglia around plaques.
To better characterize the type of inflammatory response
mediated by HJ6.3 antibody, we measured levels of several
cytokines in cortical tissue lysates. Using Rodent Cytokine
MAP kit (Myriad RBM), we measured the levels of IFN-G,
IL-1A, IL-1 B, IL-4, IL-6, IL-10, IL-12p70, and tumor necrosis factor A. Although most cytokines in the cortex were
below detection limit, levels of IFN-G, IL-1A, and IL-10
were reliably measured. Although the levels of proinflammatory cytokines (IFN-G and IL-1A) were significantly decreased by anti-apoE antibody treatment (Fig. 5, D and E),
the antiinflammatory cytokine IL-10 showed a trend toward
increased level (PBS group, 10.88 ± 1.061 pg/mg of total
protein; HJ6.3 group, 13.65 ± 1.855 pg/mg of total protein;
P = 0.21). In the 14-wk long-term treatment experiments,
HJ6.3 treatment did not cause any significant change in the
cytokine levels (unpublished data). No effect on cytokine is
likely caused by an extended time delay (10 d) between the
last antibody injection and tissue collection in the long term
treatment paradigm. Collectively, these data suggest that antiapoE immunotherapy acutely modulates inflammatory response of microglia to amyloid plaques.
2153
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34.16–56.23). In addition, there was no significant change
in apoE levels between two groups (cortex apoE in PBS
group, 6.026 ± 0.1783 ng/mg of wet brain weight; cortex
apoE in HJ6.3 group, 6.507 ± 0.3107 ng/mg of wet brain
weight; P = 0.25; 95% confidence interval, 1.340–0.3773;
plasma apoE in PBS group, 207.1 ± 25.01 μg/ml; plasma
apoE in HJ6.3 group, 192.3 ± 13.54 μg/ml; P = 0.58; 95%
confidence interval: 39.21–68.90). Body weights of both
groups were similar (PBS group, 45.57 ± 0.8226 g; HJ6.3
group, 45.26 ± 1.154 g; P = 0.8340; 95% confidence interval: 2.691–3.314). Collectively, these data indicate
that anti-apoE immunotherapy with HJ6.3, when given
weekly, does not influence brain apoE, peripheral cholesterol metabolism, and general health.
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Figure 5. Modulation of microglia activity by anti-apoE antibody treatment.
APPswe/PS1$E9 mice were intraperitoneally
injected with PBS vehicle or anti-apoE antibody (HJ6.3; 10 mg/kg) 4 times every 3 d.
(A and B) Brain sections were immunostained
for activated microglia with anti-CD45
antibody. Bar, 150 μm. (C) The extent of
microglial recruitment around plaques in
cortex was quantified after normalizing
with X-34–positive fibrillar plaque load.
(D and E) Levels of proinflammatory cytokines
(IFN-G and IL-1A) in the cortex were measured by Rodent Cytokine Multi-Analyte
Profile assay. n = 11 for PBS group; n = 9
for HJ6.3 group. Variance represents SEM.

2154

proinflammatory cytokines, leading to reduction in amyloid
accumulation.
Considering the direct effects of apoE on AB clearance
and aggregation (Kim et al., 2009a), other mechanisms could
theoretically be involved in anti-apoE antibody-mediated reduction in amyloid accumulation. Several studies demonstrated that apoE modulates AB clearance (Kim et al., 2009a).
Binding of apoE to AB may slow down AB clearance in the
brain, therefore increasing AB accumulation. This possibility
is supported by the fact that mice lacking apoE have faster AB
clearance, relative to apoE-expressing mice (DeMattos et al.,
2004). Anti-apoE antibody may bind to soluble apoE, thereby
attenuating apoE-mediated impairment of AB clearance.
Another mechanism could be related with the direct influence
of apoE on AB fibrillogenesis. Previous studies have demonstrated that apoE increases AB fibrillogenesis under certain
in vitro AB aggregation conditions (Ma et al., 1994; Wisniewski
et al., 1994; Castano et al., 1995). Anti-apoE antibody could
physically interfere with the interaction between apoE and
AB, thereby decreasing the fibrillogenic effect of apoE on AB.
A similar strategy preventing the interaction between apoE
and AB has already been successfully used to attenuate AB
toxicity and amyloid deposition (Sadowski et al., 2006). Similar
mechanisms may mediate antiamyloidogenic phenotypes observed in apoe haploinsufficient mouse models (Bien-Ly et al.,
2012; Kim et al., 2011). In the current study, we administered
anti-apoE antibody to 4-mo-old male APPswe/PS1$E9
mice when they had just started to develop amyloid deposition. Previous studies have demonstrated that anti-AB antibodies can effectively decrease amyloid accumulation when
they are given preventatively, but they are less effective in a
treatment mode (Brody and Holtzman, 2008; Golde et al.,
2009). In future studies, it will be important to determine
whether anti-apoE antibodies will prevent the detrimental
effects of apoE and have therapeutic effects on pathology,
even when the treatment begins after significant amyloid deposition occurred in the brain.
Anti-apoE antibody inhibits amyloid accumulation. | Kim et al.
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In the current study, we hypothesized that anti-apoE antibodies may have anti-amyloidogenic effects, by binding to
apoE in amyloid plaques and activating microglia-mediated
AB clearance. Weekly intraperitoneal injection of anti-apoE
antibody HJ6.3 over 14 wk dramatically reduced amyloid
plaque deposition and insoluble AB accumulation in the cortex and hippocampus, without altering plasma cholesterol
levels. These data suggest that anti-apoE immunization strategy may be further explored as a potential therapeutic strategy in AD. In addition, our finding may help further elucidate
the precise function of apoE in AD pathogenesis. Previously,
a variety of different anti-AB antibodies have been shown
to inhibit AB accumulation in mouse models of AB amyloidosis, and they are considered promising disease-modifying
therapies (Brody and Holtzman, 2008; Golde et al., 2009).
However, passive immunotherapy targeting other components of AB plaques, such as apoE, has not been previously
considered. We demonstrate that passive immunization against
AB-associated protein, apoE, can be very effective in attenuating AB accumulation. Along with a recent study using active
vaccination with ankyrin G (Santuccione et al., 2012), our
finding opens up a new avenue of research to target other
components in amyloid plaques, such as apoE, apolipoprotein
J/clusterin, and heparin sulfate proteoglycans.
Recruitment and activation of microglia around plaques
and subsequent AB degradation/clearance have been proposed
as one of the mechanisms by which AB immunotherapy decreases amyloid levels (Bard et al., 2000; Koenigsknecht-Talboo
et al., 2008; Wang et al., 2011). In our study, anti-apoE antibody HJ6.3 significantly increased CD45-positive microglia around amyloid plaques and decreased proinflammatory
cytokines. This finding suggests that anti-apoE antibody
might modulate similar inflammatory responses, which is
consistent with the effect of certain anti-AB antibodies
(Bard et al., 2000; Wilcock et al., 2004). Anti-apoE antibodies may recruit microglia to apoE-containing plaques,
triggering both direct phagocytosis and the attenuation of
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MATERIALS AND METHODS
Generation of antibodies. To generate monoclonal anti-apoE antibodies,
we first isolated apoE lipoprotein particles from primary astrocytes cultured
from C57BL6 mice (The Jackson Laboratory) using an apoE antibody (EMD
Millipore) immunoaffinity column. Purified, astrocyte-secreted, lipidated
apoE lipoprotein particles were injected with complete Freund’s adjuvant
into apoe KO mice (The Jackson Laboratory). For an initial screening of antibodies, supernatants from hybridoma cells (Y2,000 wells) were added to
96-well plates coated with purified, astrocyte-secreted, lipidated apoE lipoprotein particles. Using anti–mouse IgG-horseradish peroxidase as a detection antibody, we initially identified 36 clones, and then subcloned them to
find those that performed well in several biochemical and immunohistochemical assays. Antibody isotype was determined using a mouse monoclonal antibody isotyping kit (GE Healthcare).

Immunoprecipitation. Protein G–Sepharose 4 Fast Flow beads (GE
Healthcare) were washed with ice-cold PBS and resuspended in ice-cold
PBS. The washed 50% beads were then mixed with each HJ6 series antibodies (0.4 μg/μl of 50% bead mixture) in the presence of 1% Triton
X-100. Antibody beads were prepared by covalently binding HJ6 antibodies
to protein G–Sepharose 4 Fast Flow beads. Freshly prepared dimethyl
pimelimidate in 0.2 M triethanolamine (pH, 8.2; Sigma-Aldrich) was
added to the beads to cross-link. The beads were then washed once with
50 mM Tris (pH, 7.5) to stop the cross-linking reaction. Brain cortex
samples were lysed in 1% Triton X-100 lysis buffer (Triton X-100, 150 mM
NaCl, 50 mM Tris-HCl, 1X complete protease tablet [Roche]). After
centrifugation at 18,000 rcf for 30 min, the supernatant was collected
and used for subsequent immunoprecipitation steps. The precleared
lysates were then tumble incubated with HJ antibody-conjugated beads
for immunoprecipitation.
Immunization of mice. 4-mo-old male APPswe/PS1$E9 mice (Jankowsky
et al., 2004) were intraperitoneally injected weekly for 14 wk with PBS
or anti-apoE antibody (HJ6.3) at 10 mg of antibody/kg of body weight
dose. Working stock of antibody was freshly prepared on the date of injection at 1 mg/ml concentration. Brain tissues were collected 10 d after
the last injection. For a short-term experiment, nine-month-old male
APPswe/PS1$E9 mice were intraperitoneally injected 4 times every 3 d,
and brain tissues were collected 24 h after the last injection. All animal
experiments were approved by the animal study committee at Washington
University in St. Louis.
Measurement of HJ6.3 antibody levels in cerebral cortex and plasma.
4-mo-old APPswe/PS1$E9 mice were intraperitoneally injected one time
with biotinylated anti-apoE antibody (HJ6.3) at 10 mg of antibody/kg of
body weight dose. After perfusion, cerebral cortical tissues were collected
24 h after injection, and then sonicated with PBS (100 mg of wet weight/ml of
PBS). PBS lysates and plasma samples were loaded to anti–mouse IgG antibodycoated plate (10 μg/ml; Jackson ImmunoResearch Laboratories), and biotinylated HJ6.3 antibody was detected with poly-horseradish peroxidase streptavidin
(Thermo Fisher Scientific) and Super Slow 3,3,5,5-tetramethylbenzidine
(Sigma-Aldrich).
JEM Vol. 209, No. 12

Quantitative analysis of CD45 staining. Brain sections cut with a freezing sliding microtome were immunostained with anti-CD45 antibody
(1:500 dilution; AbD Serotec). Stained brain sections were scanned with a
NanoZoomer slide scanner (Hamamatsu Photonics) at 40× magnification
setting. The percent area covered by CD45 staining was analyzed in the cortex by using NDP viewer, ACDSee Pro 2, and ImageJ softwares, as described
in the previous section. Three brain sections per mouse, each separated by
300 μm, were used for quantification. The mean of three sections was used
to estimate the area covered by immunoreactivity. All analyses were performed in a blinded fashion after stained images were thresholded to minimize false-positive signals.
Measurement of IFN-G and IL-1A. 9-mo-old male APPswe/PS1$E9
mice were intraperitoneally injected 4 times every 3 d, and brain tissues were
collected 24 h after the last injection. Cerebral cortical tissues were lysed
by sonication (3-s pulse, 5 times, 35% amplitude) with lysis buffer (50 mM
Tris-HCL, 2 mM EDTA, 1 μg/ml leupeptin, 1 μg/ml aprotinin, 0.25 mM
phenylmethanesulfonyl fluoride, pH 7.4). Homogenates were centrifuged
for 10 min at 14,000 RPM. Supernatants were used to measure IFN-G and
IL-1A levels using Rodent Cytokine Multi-Analyte Profile (Myriad RBM).
AB and apoE ELISA. Cortical and hippocampal tissues were sequentially
homogenized with PBS and 5 M guanidine buffer in the presence of 1X
protease inhibitor mixture (Roche). The levels of insoluble AB in a 5-M
guanidine fraction were measured by sandwich ELISA. For AB ELISA, HJ2
(anti–AB35-40) and HJ7.4 (anti–AB37-42) were used as capture antibodies,
and HJ5.1-biotin (anti–AB13-28) was used as the detection antibody. ApoE
levels in the plasma and cortical tissue PBS lysates were measured using apoE
ELISA. HJ6.2 and HJ6.3 antibodies were used for capture and detection, respectively. Pooled C57BL/6J plasma was used as a standard for murine apoE
quantification (Kim et al., 2009b).
Total cholesterol assay. 10 μl of plasma from each mouse was mixed
with 1 ml of Color Reagent (Wako Chemicals USA), containing 1.6 U/ml
cholesterol ester hydrolase, 0.31 U/ml cholesterol oxidase, 5.2 U/ml
peroxidase, 0.19 mmol/l 4-aminoantipyrine, 4.4 U/ml ascorbate oxidase,
and 0.95 mmol/l 3,5-dimethoxy-N-ethyl-N-(2-hydroxy-3-sulfopropyl)
aniline sodium. After 5 min incubation at 37°C, absorbances of samples
and standards were measured at 600 nm. Total cholesterol levels were
calculated based on the standard curve.
Statistical analyses. To determine the statistical significance (*, P < 0.05;
**, P < 0.01; ***, P < 0.001), two-tailed Student’s t test was used (GraphPad
Prism 5.0), after testing the equal variance test (Levene median test) and
2155
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Immunoblotting. Cerebral cortical tissues from wild-type and apoe KO
mice were lysed with RIPA lysis buffer (1% NP-40, 1% sodium deoxycholate, 0.1% SDS, 25 mM Tris-HCl, and 150 mM NaCl) in the presence of 1X
protease inhibitor mixture (Roche). Tissue homogenates were centrifuged at
18,000 rcf for 30 min. Protein concentration in supernatants was determined
using the BCA protein assay kit (Thermo Fisher Scientific). Equal amount of
total proteins were run on 4–12% Bis-Tris XT gels (Bio-Rad Laboratories)
and transferred to nitrocellulose membranes. Blots were probed with antiapoE antibodies HJ6.1, HJ6.2, HJ6.3, or HJ6.4, as indicated in the figure.
Equal amount of anti-apoE antibodies were used as a primary antibody to
detect apoE in Western blotting. Blots were simultaneously exposed for the
same period of time.

Histology and quantitative analysis of AB plaques. Brain hemispheres
were placed in 30% sucrose before freezing and cutting on a freezing sliding
microtome. Serial coronal sections at 50-μm intervals were collected from
the rostral anterior commissure to caudal hippocampus. Sections were
stained with biotinylated 82E1 (anti-AB1-16) antibody (1:500 dilution; IBL
International) or X-34 dye. Stained brain sections were scanned with a
NanoZoomer slide scanner (Hamamatsu Photonics) at 20× magnification
setting. For quantitative analyses of 82E1-biotin and X-34 staining, scanned
images were exported using NDP viewer software (Hamamatsu Photonics)
and converted to 8-bit grayscale using ACDSee Pro 2 software (ACD Systems). All converted images were uniformly thresholded to highlight plaques,
and then analyzed by “Analyze Particles” function in the ImageJ software
(National Institutes of Health). Identified objects after thresholding were individually inspected to confirm the object as a plaque or not. 3 brain sections
per mouse, each separated by 300 μm, were used for quantification. These
sections correspond approximately to sections at Bregma 1.7, 2.0, and
2.3 mm in the mouse brain atlas. The mean of three sections was used to
represent a plaque load for each mouse. For analysis of AB plaque in the cortex, the cortex immediately dorsal to the hippocampus was assessed. All
analyses were performed in a blinded manner.
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normality test (Kolmogorov-Smirnov test; SigmaStat 3.0.). Variability of the
measurements was reported as SEM.
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